DZ2410A1 - Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques - Google Patents

Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques

Info

Publication number
DZ2410A1
DZ2410A1 DZ980020A DZ980020A DZ2410A1 DZ 2410 A1 DZ2410 A1 DZ 2410A1 DZ 980020 A DZ980020 A DZ 980020A DZ 980020 A DZ980020 A DZ 980020A DZ 2410 A1 DZ2410 A1 DZ 2410A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
acid derivatives
derivatives process
arylsulfonylaminohydroxamic
Prior art date
Application number
DZ980020A
Other languages
English (en)
Inventor
Ralph Pelton Robbinson Jr
Kim Francis Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2410A1 publication Critical patent/DZ2410A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
DZ980020A 1997-02-03 1998-02-02 Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques DZ2410A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3685797P 1997-02-03 1997-02-03

Publications (1)

Publication Number Publication Date
DZ2410A1 true DZ2410A1 (fr) 2003-01-04

Family

ID=21891041

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980020A DZ2410A1 (fr) 1997-02-03 1998-02-02 Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques

Country Status (43)

Country Link
US (1) US6303636B1 (fr)
EP (1) EP0977733B1 (fr)
JP (1) JP3765584B2 (fr)
KR (1) KR100317146B1 (fr)
CN (1) CN1113862C (fr)
AP (1) AP826A (fr)
AR (1) AR011101A1 (fr)
AT (1) ATE248812T1 (fr)
AU (1) AU721748B2 (fr)
BG (1) BG64308B1 (fr)
BR (1) BR9807815A (fr)
CA (1) CA2279276C (fr)
CO (1) CO4920234A1 (fr)
DE (1) DE69817801T2 (fr)
DK (1) DK0977733T3 (fr)
DZ (1) DZ2410A1 (fr)
EA (1) EA002594B1 (fr)
ES (1) ES2202796T3 (fr)
GT (1) GT199800025A (fr)
HK (1) HK1026203A1 (fr)
HN (1) HN1998000011A (fr)
HR (1) HRP980058B1 (fr)
HU (1) HUP0000852A2 (fr)
ID (1) ID22799A (fr)
IL (2) IL131042A (fr)
IS (1) IS1950B (fr)
MA (1) MA26471A1 (fr)
MY (1) MY121754A (fr)
NO (1) NO313631B1 (fr)
NZ (1) NZ336840A (fr)
OA (1) OA11081A (fr)
PA (1) PA8445801A1 (fr)
PE (1) PE57799A1 (fr)
PL (1) PL335027A1 (fr)
PT (1) PT977733E (fr)
SK (1) SK283963B6 (fr)
TN (1) TNSN98019A1 (fr)
TR (1) TR199901849T2 (fr)
TW (1) TW509668B (fr)
UA (1) UA63935C2 (fr)
UY (1) UY24866A1 (fr)
WO (1) WO1998033768A1 (fr)
ZA (1) ZA98823B (fr)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746877B2 (en) * 1997-07-31 2002-05-02 Procter & Gamble Company, The Acyclic metalloprotease inhibitors
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1147085B1 (fr) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Derives d'acide hydroxamique alkynyles, leur elaboration et leur utilisation comme inhibiteurs des metalloproteinases matrices ou inhibiteurs des tace (enzymes de conversion du facteur de necrose tumorale alpha)
JP2002538136A (ja) 1999-03-03 2002-11-12 ザ プロクター アンド ギャンブル カンパニー アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤
US6566381B1 (en) 1999-03-03 2003-05-20 The Procter & Gamble Company Hetero-substituted metalloprotease inhibitors
WO2000058280A1 (fr) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
DE60003863T2 (de) 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
DE60006523T2 (de) 1999-05-28 2004-08-12 Pfizer Products Inc., Groton `3-(arylsulfonylamino)-tetrahydropyran-3-carbonsäure hydroxamide
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001070691A1 (fr) 2000-03-21 2001-09-27 The Procter & Gamble Company Inhibiteurs de metalloproteases n-substitues renfermant une chaine laterale heterocyclique
IL151124A0 (en) * 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
AU2001290131B2 (en) * 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
EP1348443A4 (fr) * 2000-12-08 2005-07-06 Takeda Pharmaceutical Medicaments combines
CA2433800C (fr) 2001-01-05 2016-09-13 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002361096A1 (en) * 2001-12-27 2003-07-15 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
CA2472578A1 (fr) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combinaison anticancereuse et son utilisation
DE10206404A1 (de) * 2002-02-14 2003-08-28 Gruenenthal Gmbh Synthese von substituierten Sulfonylaminen
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
PL377713A1 (pl) 2002-12-19 2006-02-06 Pfizer Inc. Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
JP2006517216A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用剤とｔａｃｅ阻害剤に基づく新規な医薬組成物
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005051302A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
DK1786785T3 (da) 2004-08-26 2010-05-31 Pfizer Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
KR20080019236A (ko) 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
KR20080104347A (ko) * 2006-03-29 2008-12-02 노파르티스 아게 선택적 히드록사메이트-기재 ｍｍｐ 억제제
WO2007121269A2 (fr) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyle sulfamides utilisés comme inhibiteurs de mek
ATE483463T1 (de) 2006-04-18 2010-10-15 Ardea Biosciences Inc Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
JP2010513263A (ja) 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク ベンズイミダゾール誘導体
JP5491199B2 (ja) 2007-01-19 2014-05-14 アルデア バイオサイエンシズ，インコーポレイティド Ｍｅｋのインヒビター
WO2008129380A1 (fr) 2007-04-18 2008-10-30 Pfizer Products Inc. Dérivés de sulfonyle amide pour le traitement d'une croissance cellulaire anormale
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
TWI446905B (zh) * 2007-06-05 2014-08-01 Sanofi Aventis 經取代之苯甲醯基胺基－氫茚－２－羧酸及相關化合物
CA2694646C (fr) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
CN101945870B (zh) 2007-12-19 2012-10-03 健泰科生物技术公司 5-苯氨基咪唑并吡啶和使用方法
CN101945875B (zh) 2007-12-21 2013-04-24 健泰科生物技术公司 氮杂吲嗪及其使用方法
EP3613743B1 (fr) 2008-01-04 2022-03-16 Intellikine, LLC Procédés de préparation de dérivés de 1h-pyrazolo[3,4-d]pyrimidin-4-amine
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
CA2756690C (fr) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration de compositions de benzodiazepine
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5977522B2 (ja) 2009-02-05 2016-08-24 イミュノジェン・インコーポレーテッド 新規ベンゾジアゼピン誘導体
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
EP2400990A2 (fr) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
CA2756566A1 (fr) 2009-03-27 2010-09-30 Ardea Biosciences, Inc. Sulfonamides de dihydropyridine comme inhibiteurs de mek
CA2760791C (fr) 2009-05-07 2017-06-20 Intellikine, Inc. Composes heterocycliques et leurs utilisations
US20120128670A1 (en) 2009-07-31 2012-05-24 OSI Pharmaceuticals, LLC mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
EP2467141B1 (fr) 2009-08-17 2018-10-31 Intellikine, LLC Composés hétérocycliques et leurs utilisations
WO2011027249A2 (fr) 2009-09-01 2011-03-10 Pfizer Inc. Dérivés de benzimidazole
WO2011047055A2 (fr) 2009-10-13 2011-04-21 Allostem Therapeutics Llc Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
EA027123B1 (ru) 2009-11-05 2017-06-30 Ризен Фармасьютикалз С.А. Ингибиторы киназы pi3k
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
ES2753748T3 (es) 2010-02-12 2020-04-14 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CA2783656A1 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1
EP2542893A2 (fr) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
EP2571878B1 (fr) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Nouveau composés de 3,5-disubstitués-3h-imidazo[4,5-b]pyridine et 3,5- disubstitués -3h-[1,2,3]triazolo[4,5-b]pyridine utilisés comme modulateurs des protéines kinases
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103068851B (zh) 2010-06-16 2015-03-11 高等教育联邦***-匹兹堡大学 内质蛋白的抗体及其用途
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2012052948A1 (fr) 2010-10-20 2012-04-26 Pfizer Inc. Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
WO2012064973A2 (fr) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et utilisations de ceux-ci
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
SG10201601046QA (en) 2011-02-15 2016-03-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2678016B1 (fr) 2011-02-23 2016-08-10 Intellikine, LLC Composés hétérocycliques et leurs utilisations
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
EP3415139B8 (fr) 2011-06-14 2022-05-18 Neurelis, Inc. Administration de benzodiazépine
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
CA2847540C (fr) 2011-09-22 2016-05-17 Pfizer Inc. Derives de pyrrolopyrimidine et de purine
WO2013049332A1 (fr) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibiteurs de monoacylglycérol lipase et procédés de leur utilisation
EP3275902A1 (fr) 2011-10-04 2018-01-31 IGEM Therapeutics Limited Anticorps ige anti-hmw-maa
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
EP2817004B1 (fr) 2012-02-22 2018-04-11 The Regents of The University of Colorado, A Body Corporate Dérivés de bouvardine et leurs utilisations thérapeutiques
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2859017B1 (fr) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014031566A1 (fr) 2012-08-22 2014-02-27 Immunogen, Inc. Dérivés de benzodiazépine cytotoxique
KR102182800B1 (ko) 2012-08-31 2020-11-25 서트로 바이오파마, 인크. 아지도 기를 포함하는 변형된 아미노산
EP2909181B1 (fr) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Modulateurs de pkm2 et procédés pour les utiliser
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961434A2 (fr) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
EP2970205B1 (fr) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014194030A2 (fr) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PT3052096T (pt) 2013-10-03 2018-04-04 Kura Oncology Inc Inibidores de erk e métodos de utilização
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JP6559123B2 (ja) 2013-10-10 2019-08-14 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの阻害剤
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (fr) 2014-04-10 2015-10-15 Pfizer Inc. Dérivés de dihydropyrrolopyrimidine
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
MX2016014143A (es) 2014-04-30 2017-02-15 Pfizer Derivados de diheterociclo enlazado a cicloalquilo.
CA2949793C (fr) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Composes heteroaryle d'inhibition de la kinase
WO2016001789A1 (fr) 2014-06-30 2016-01-07 Pfizer Inc. Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
CN106999578B (zh) 2014-07-31 2022-03-04 美国政府(由卫生和人类服务部的部长所代表) 针对epha4的人类单克隆抗体和其用途
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (fr) 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
TW201702232A (zh) 2015-04-10 2017-01-16 亞瑞克西斯製藥公司 經取代之喹唑啉化合物及其使用方法
CA2982360A1 (fr) 2015-04-15 2016-10-20 Liansheng Li Inhibiteurs tricycliques condenses de kras et procedes pour les utiliser
KR20180018507A (ko) 2015-04-20 2018-02-21 톨레로 파마수티컬스, 인크. 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
WO2016178876A2 (fr) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
MX2017014645A (es) 2015-05-18 2018-01-23 Tolero Pharmaceuticals Inc Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2017009751A1 (fr) 2015-07-15 2017-01-19 Pfizer Inc. Dérivés de pyrimidine
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017024073A1 (fr) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Thérapies combinatoires pour le traitement du cancer
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356339A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines mutantes kras g12c
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017058768A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017058792A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017070256A2 (fr) 2015-10-19 2017-04-27 Araxes Pharma Llc Méthode de criblage d'inhibiteurs de ras
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
KR20180100125A (ko) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. Mtap 널 암을 치료하기 위한 mat2a 억제제
WO2017100546A1 (fr) 2015-12-09 2017-06-15 Araxes Pharma Llc Procédés de préparation de dérivés de quinazoléine
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
ES2695533T3 (es) 2016-02-01 2019-01-08 Galderma Res & Dev Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
RS64261B1 (sr) 2016-03-16 2023-07-31 Kura Oncology Inc Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe
BR112018068702A2 (pt) 2016-03-16 2019-01-15 Kura Oncology Inc inibidores bicíclicos em ponte de menin-mll e métodos de uso
WO2017172979A1 (fr) 2016-03-30 2017-10-05 Araxes Pharma Llc Composés quinazoline substitués et procédés d'utilisation
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
WO2017201302A1 (fr) 2016-05-18 2017-11-23 The University Of Chicago Mutation de btk et résistance à l'ibrutinib
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
AU2017321973A1 (en) 2016-09-02 2019-03-07 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018064510A1 (fr) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2018068017A1 (fr) 2016-10-07 2018-04-12 Araxes Pharma Llc Composés hétérocycliques en tant qu'inhibiteurs de ras et leurs procédés d'utilisation
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
WO2018098352A2 (fr) 2016-11-22 2018-05-31 Jun Oishi Ciblage d'expression du point de contrôle immunitaire induit par kras
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
MA47107B1 (fr) 2016-12-22 2021-11-30 Amgen Inc Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
CN110461872B (zh) 2017-01-26 2023-09-26 再鼎医药(上海)有限公司 Cd47抗原结合单元及其用途
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
EP3573964A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
EP3630747A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3658588A1 (fr) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Méthodes d'utilisation d'anticorps anti-cd74 et de conjugués d'anticorps dans le traitement d'un lymphome à cellules t
IL272512B (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3684814A1 (fr) 2017-09-18 2020-07-29 Sutro Biopharma, Inc. Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
JP7424637B2 (ja) 2017-11-10 2024-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｎｓｄファミリー阻害物質及びそれによる治療の方法
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CA3098574A1 (fr) 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
MX2020011582A (es) 2018-05-04 2020-11-24 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
US10988485B2 (en) 2018-05-10 2021-04-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
CN112533581A (zh) 2018-06-07 2021-03-19 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
WO2020028706A1 (fr) 2018-08-01 2020-02-06 Araxes Pharma Llc Composés hétérocycliques spiro et procédés d'utilisation correspondants pour le traitement du cancer
EP3852811A1 (fr) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Polythérapies avec des conjugués d'anticorps anti-récepteur du folate
CN113207291A (zh) 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (fr) 2018-11-19 2020-05-28 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005924A (es) 2018-11-29 2021-06-30 Araxes Pharma Llc Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
CA3119807A1 (fr) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destines a etre utilises en tant qu'agents pour le traitement du cancer
CA3123871A1 (fr) 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
WO2020132651A1 (fr) 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
EP3898592A1 (fr) 2018-12-20 2021-10-27 Amgen Inc. Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MX2021007158A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
CA3127502A1 (fr) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
WO2020180768A1 (fr) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Composés hétéroaryle bicycliques et leurs utilisations
KR20210146288A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로사이클릴 화합물 및 이의 용도
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
KR20210141621A (ko) 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
WO2020227105A1 (fr) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Conjugués d'anticorps anti-bcma
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
BR112021023277A2 (pt) 2019-05-21 2022-01-04 Amgen Inc Formas em estado sólido
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
JP2022542394A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
CA3146693A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
AU2020325115A1 (en) 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
WO2021067215A1 (fr) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Composés de pipéridine utilisés en tant qu'inhibiteurs de ménine
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
WO2021086833A1 (fr) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Inhibiteurs à petites molécules de mutant de kras g12c
CN115551500A (zh) 2019-10-31 2022-12-30 大鹏药品工业株式会社 4-氨基丁-2-烯酰胺衍生物及其盐
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
TW202132315A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras 抑制劑
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
US20230192681A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (fr) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. Composé ayant une activité inhibitrice contre la mutation kras g12d
CA3163703A1 (fr) 2020-01-07 2021-07-15 Steve Kelsey Dosage d'inhibiteurs de shp2 et methodes de traitement du cancer
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
WO2021178597A1 (fr) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
WO2021207310A1 (fr) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Inhibiteurs de la ménine et procédés d'utilisation pour le traitement du cancer
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021215544A1 (fr) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Inhibiteurs de protéine kras g12d
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
CA3185209A1 (fr) 2020-07-10 2021-01-27 Alyssa WINKLER Inhibiteurs de gas41 et leurs methodes d'utilisation
JP7373664B2 (ja) 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
KR20230170039A (ko) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
KR20240004659A (ko) 2021-04-30 2024-01-11 셀진 코포레이션 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
EP4347041A1 (fr) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Petites molécules inhibitrices de protéines mutées par kras
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023056589A1 (fr) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Inhibiteurs de ménine et procédés d'utilisation pour le traitement du cancer
WO2023114954A1 (fr) 2021-12-17 2023-06-22 Genzyme Corporation Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2
EP4227307A1 (fr) 2022-02-11 2023-08-16 Genzyme Corporation Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023211812A1 (fr) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Dérivés hétérocycliques en tant qu'inhibiteurs de protéine kinase activée par mitogène (mek)
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
US20240058465A1 (en) 2022-06-30 2024-02-22 Sutro Biopharma, Inc. Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
WO2024010925A2 (fr) 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Inhibiteurs de protéine kinase activée par mitogène (mek)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE212619T1 (de) * 1996-10-22 2002-02-15 Upjohn Co Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
ES2190115T3 (es) * 1997-11-12 2003-07-16 Darwin Discovery Ltd Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf.
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
ES2220004T3 (es) * 1998-04-10 2004-12-01 Pfizer Products Inc. Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico.
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico

Also Published As

Publication number Publication date
ES2202796T3 (es) 2004-04-01
PA8445801A1 (es) 2000-05-24
HN1998000011A (es) 1999-02-09
ATE248812T1 (de) 2003-09-15
TW509668B (en) 2002-11-11
AU8191798A (en) 1998-08-25
BG64308B1 (bg) 2004-09-30
AP9801191A0 (en) 1998-03-31
IL131042A (en) 2004-07-25
UA63935C2 (uk) 2004-02-16
CN1113862C (zh) 2003-07-09
JP3765584B2 (ja) 2006-04-12
EA199900604A1 (ru) 2000-04-24
BR9807815A (pt) 2000-03-08
HRP980058B1 (en) 2002-04-30
IS5129A (is) 1999-07-23
DE69817801D1 (en) 2003-10-09
US6303636B1 (en) 2001-10-16
OA11081A (en) 2002-03-14
ZA98823B (en) 1999-08-02
CA2279276A1 (fr) 1998-08-06
CO4920234A1 (es) 2000-05-29
SK101299A3 (en) 2002-04-04
EA002594B1 (ru) 2002-06-27
MA26471A1 (fr) 2004-12-20
JP2000508350A (ja) 2000-07-04
DE69817801T2 (de) 2004-03-11
MY121754A (en) 2006-02-28
EP0977733A1 (fr) 2000-02-09
IS1950B (is) 2004-10-13
HK1026203A1 (en) 2000-12-08
EP0977733B1 (fr) 2003-09-03
AR011101A1 (es) 2000-08-02
NO993730D0 (no) 1999-08-02
PL335027A1 (en) 2000-03-27
NZ336840A (en) 2001-01-26
CA2279276C (fr) 2005-09-13
UY24866A1 (es) 2000-09-29
PE57799A1 (es) 1999-06-11
DK0977733T3 (da) 2003-11-24
KR20000070721A (ko) 2000-11-25
AU721748B2 (en) 2000-07-13
IL131042A0 (en) 2001-01-28
AP826A (en) 2000-04-28
WO1998033768A1 (fr) 1998-08-06
NO993730L (no) 1999-10-01
HUP0000852A2 (hu) 2001-05-28
TR199901849T2 (xx) 2000-02-21
BG103616A (en) 2000-02-29
ID22799A (id) 1999-12-09
KR100317146B1 (ko) 2001-12-22
NO313631B1 (no) 2002-11-04
CN1249743A (zh) 2000-04-05
PT977733E (pt) 2003-12-31
TNSN98019A1 (fr) 2005-03-15
SK283963B6 (sk) 2004-06-08
HRP980058A2 (en) 1998-12-31
GT199800025A (es) 1999-07-24

Similar Documents

Publication Publication Date Title
DZ2410A1 (fr) Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2416A1 (fr) Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2870A1 (fr) Dérivés d'acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.
DZ2394A1 (fr) Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2596A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procédé pour leur préparation.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2595A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs et procédépour leur préparation.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2758A1 (fr) Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2360A1 (fr) Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2227A1 (fr) Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.